iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Friday. The company traded as high as $109.43 and last traded at $108.1960, with a volume of 31,871 shares trading hands. The stock had previously closed at $106.61.
iShares U.S. Pharmaceuticals ETF Price Performance
The company has a 50 day moving average of $102.38 and a 200-day moving average of $94.63. The company has a market cap of $1.62 billion, a P/E ratio of 17.75 and a beta of 0.47.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Heritage Oak Wealth Advisors LLC purchased a new stake in iShares U.S. Pharmaceuticals ETF during the 1st quarter valued at $530,000. Schuylkill Financial LLC purchased a new stake in iShares U.S. Pharmaceuticals ETF in the 2nd quarter worth $992,000. Tidal Investments LLC purchased a new position in iShares U.S. Pharmaceuticals ETF in the 2nd quarter worth approximately $3,716,000. Bank of America Corp DE grew its stake in iShares U.S. Pharmaceuticals ETF by 2.8% during the first quarter. Bank of America Corp DE now owns 456,606 shares of the company’s stock valued at $39,579,000 after acquiring an additional 12,565 shares in the last quarter. Finally, Compass Financial Management LLC purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF in the second quarter worth about $565,000.
iShares U.S. Pharmaceuticals ETF Company Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
See Also
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
- Silicon Shock: Intel’s 25% Valuation Reset
- Advanced Micro Devices’ Meta Platforms Partnership Goes Beyond a $1 Billion Investment
- Chipotle’s $32 Floor: Is a Major Stock Rebound Coming?
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
